Cart
sales@molnova.com
NVP-TNKS656
CAS No. 1419949-20-4
NVP-TNKS656( NVPTNKS656 | TNKS656 | TNKS656 )
Catalog No. M17287 CAS No. 1419949-20-4
NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 85 | In Stock |
|
| 2MG | 49 | In Stock |
|
| 5MG | 77 | In Stock |
|
| 10MG | 124 | In Stock |
|
| 25MG | 261 | In Stock |
|
| 50MG | 435 | In Stock |
|
| 100MG | 638 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNVP-TNKS656
-
NoteResearch use only, not for human use.
-
Brief DescriptionNVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor.
-
DescriptionNVP-TNKS656, also known as TNKS656, is a potent and orally active Tankyrase Inhibitor. With an enthalpy-driven thermodynamic signature of binding, highly favorable physicochemical properties, and high lipophilic efficiency, NVP-TNKS656 is well suited for further in vivo validation studies. Bioactivity of TNKS656: TNKS2 IC50 = 6nM, LiPE = 7.0, HEK298 STF IC50 = 3.5nM, Cmax/ Cellular IC50 = 23,000.
-
In Vitro——
-
In Vivo——
-
SynonymsNVPTNKS656 | TNKS656 | TNKS656
-
PathwayNeuroscience
-
TargetGamma-secretase
-
RecptorTNKS2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1419949-20-4
-
Formula Weight494.58
-
Molecular FormulaC27H34N4O5
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 40 mg/mL. 80.88 mM
-
SMILESCOc1ccc(cc1)C(=O)C1CCN(CC(=O)N(CC2CC2)Cc2nc(=O)c3c(CCOC3)[nH]2)CC1
-
Chemical NameN-(cyclopropylmethyl)-2-(4-(4-methoxybenzoyl)piperidin-1-yl)-N-((4-oxo-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-2-yl)methyl)acetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Shultz MD, et al. J Med Chem. 2013, 56(16), 6495-6511.
molnova catalog
related products
-
Monomethyl auristati...
Monomethyl auristatin E (MMAE), an antimitotic agent, inhibits cell division by blocking the polymerization of tubulin and also has inhibition of antibody-drug conjugates (ADCs) activity.
-
Brontictuzumab
Brontictuzumab (OMP 52M5) is a monoclonal antibody that targets Notch1 and inhibits activation of the pathway.
-
Enoticumab
Enoticumab (REGN421) is a fully human IgG1 monoclonal antibody with anticancer activity that inhibits the growth of cancer cells.Enoticumab binds human Dll4 and disrupts Notch-mediated signaling.
